Carol Suh

Carol Suh is one of Neumora’s co-founders and has held roles of increasing responsibility at the company since its inception, including her current role as Chief Strategy Officer. In addition to her role at Neumora, Ms. Suh is a Partner at ARCH Venture Partners, where she has helped to build multiple companies across the fields of cell and gene therapy, neuroscience, oncology and immunology. Ms. Suh is a co-founder of Orbital Therapeutics and serves as a member of its board of directors. Additionally, she served as a member of the board of directors of HI-Bio until the company’s ~$1.8B acquisition by Biogen in 2024. Prior to ARCH, Ms. Suh helped launch Magenta Therapeutics, a biotechnology company, and held roles at Trinity Partners and GlaxoSmithKline. Ms. Suh holds an A.B. in Molecular and Cellular Biology from Harvard University, where she trained under Dr. David Scadden at the Harvard Stem Cell Institute, an M.Phil. from Yale University, where she was awarded the National Science Foundation Graduate Research Fellowship for her work in stem cell biology, and an M.B.A. from Stanford Graduate School of Business.